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Summary 
Leishmania  braziliensis causes cutaneous and mucosal leishmaniasis in humans. Most patients with 
cutaneous leishmaniasis heal spontaneously and may therefore have developed protective immunity. 
There appears to be a mixed cytokine profile associated with active cutaneous or mucosal disease, 
and a dominant T helper (Th)l-type response associated with healing. Leishmanial antigens that 
elicit these potent proliferative and cytokine responses from peripheral blood mononuclear cells 
(PBMC) are now being identified. Herein, we report on the cloning and expression of a L. braziliensis 
gene homologous to the eukaryotic ribosomal protein elF4A (LelF) and patient PBMC responses 
to rLelF.  Patients with  mucosal and  self-healing  cutaneous disease had  significantly  higher 
proliferative responses than those with cutaneous lesions. Whereas the parasite lysate stimulated 
patient PBMC to produce a mixed Thl/Th2-type cytokine profile, LelF stimulated the production 
of interferon ~/(IFN-3'), interleukin 2 (IL-2), and tumor necrosis factor ot but not IL-4 or IL-10. 
Recombinant 1.elF (rLelF)  downregulated both  IL-10  mlLNA in  the  "resting"  PBMC  of 
leishmaniasis patients and LPS-induced IL-10 production by patient PBMC. rLelF also stimulated 
the production of IL-12 in cultured PBMC from both patients and uninfected individuals.  The 
production of IFN-3' by patient PBMC stimulated with either rLelF or parasite lysate was IL-12 
dependent, whereas anti-IFN-3,  monoclonal antibody only partially blocked the LelF-induced 
production of IL-12. In vitro production of both IFN-'y and IL-12 was abrogated by exogenous 
human recombinant IL-10. Therefore, we have identified a recombinant leishmanial antigen that 
elicits IL-12 production and Thl-type responses in patients as well as IL-12 production in normal 
human PBMC. 
L 
ishmania are obligate intracellular protozoan parasites of 
macrophages that cause a spectrum of human diseases, 
including self-healing  skin lesions,  diffuse  cutaneous and 
mucosal manifestations, or severe visceral disease (1). Leish- 
mania braziliensis commonly  causes localized cutaneous leish- 
maniasis (CL) 1. Most patients with CL heal spontaneously 
(2). However, a chronic mucosal leishmaniasis (ML) develops 
in some infected individuals, with severe and progressive de- 
struction of the nasal, oral, and/or pharyngeal mucous mem- 
branes (3, 4). Patients with CL generally have positive delayed 
hypersensitivity and in vitro proliferative responses to leish- 
1  Abbreviations used in this paler: CL, cutaneous  leishmaniasis; LelF, L. 
braziliensis homologue of the eukaryotic initiation  factor 4A; ML, mucosal 
leishmaniasis; rAg, recombinant antigen; rLelF, recombinant  LeIF. 
manial Ag during both active and cured infection. These re- 
sponses are often exaggerated  in ML patients (5, 6). 
The induction of Thl effector cells capable of activating 
macrophages to a microbicidal state is necessary for eliminating 
these intramacrophage parasites. In experimental leishmani- 
asis, immunological interventions to direct CD4 § T cell re- 
sponse must be administered before the establishment of Thl 
or Th2 effector subsets. IL-12, which facilitates the develop- 
ment of Thl responses  by stimulating the production of IFN-'y 
while downregulating the production of IL-4,  has  been 
demonstrated to cure susceptible BALB/c mice against L. major 
infection (7, 8), whereas neutralization of IL-12 made resis- 
tant mice susceptible to infection (8). Although neutraliza- 
tion of IFN-3' abrogates the natural resistance of C3H/HeN 
mice to infection with L. major (9), by itself, IFN-7 did not 
confer protection to susceptible  mice (10). 
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maniasis patients with different clinical presentations as well 
as the identification of defined Ag that induce and elicit cell- 
mediated immune responses is important to our understanding 
of the nature of immune responsiveness during infection, as 
well as the potential identification of vaccine molecules. The 
elucidation of cytokines associated with Thl and/or Th2 re- 
sponses by defined L.  braziliensis  Ag in patients with leish- 
manial infections has not been previously described. Because 
the course of human infection with L. braziliensis  is variable, 
ranging from self-healing infection to chronic disease, it is an 
excellent system in which to study immunoregulatory aspects 
of leishmaniasis, including the effects of parasite Ag on host 
responses.  In the present study, Leishmania-specific  PBMC 
responses in patients representing a spectrum ofL. braziliensis 
infection were  analyzed.  A  leishmanial  Ag,  L.  braziliensis 
homologue  of the  eukaryotic  initiation  factor  4A  (LelF), 
capable of stimulating  strong Thl-type responses in leish- 
maniasis patients' PBMC as well as IL-12 production in pa- 
tient  and  nonpatient  cells,  was identified. 
Materials and Methods 
Parasites.  L. braziliensis (MHOM/BR/75/M2903),  L. guyanensis 
(MHOM/BR/75/M4147), L. amazonensis (IFLA/BR/67/PH8), 
L. chagasi (MHOM/BR/82/BA-2, C1 and MHOM/BR/84/Jonas), 
L. donovani (MHOM/Et/67/HU3), L. infantum (IPT-1), L. major 
(LTM p-2), L. tropica (1063C),  Trypanosoma cruzi (MHOM/CH/ 
00/Tulahuen C2), and T  brucei (TREU 667) were used (11). Pro- 
mastigotes of Leishmania and epimastigotes of T. cruzi were cul- 
tured in axenic media.  L. chagasi and L. amazonensis amastigotes 
were obtained from spleens  of Syrian hamster and  footpads of 
BALB/c ByJ mice,  respectively. 
Library Construction and Isolation of Genomic Clones.  A genomic 
expression library with sheared DNA from L. braziliensis (MHOM/ 
BR/75/M2903) was constructed in bacteriophage ZAPII (Strata- 
gene, La Jolla, CA). The expression library was screened with Esch- 
erichia coil adsorbed sera from patient with ML due to infection 
with L. braziliensis. A plaque containing an immunoreactive recom- 
binant antigen (rAg) (LelF.1) was purified, the pBSK(-) phagemid 
excised, nested deletions generated using Exonuclease III for single- 
stranded template preparations  and sequencing (12). Clone pLelE1 
lacked the first 48 amino acid residues (144 nucleotides) of the full- 
length sequence. The insert was subsequently used to isolate the 
full-length genomic sequence. 
Expression and Purification of Recombinant LelF (rLelF).  The 45- 
kD rag of the LelF.1 genomic clone was  purified from 500 ml 
of isopropyl ~ D-thiogalactoside  (IFFG)-induced cultures (12). In- 
clusion bodies were isolated and sequentially washed in TNE (50 
mM Tris, pH 8.0, 100 mM NaC1, and 10 mM EDTA) containing 
2, 4, and 8 M urea. Fractions containing solubilized  rAg (usually 
the 8 M cut) were pooled, dialyzed against Tris-buffered saline (TBS), 
and concentrated by ~recipitation with 30% ammonium sulfate. 
Purification to homogeneity was accomplished by preparative SDS- 
PAGE electrophoresis,  followed by excision and electroelution of 
the rAg as described.  All Ag used in our studies  had negligible 
(<10 pg/ml) endotoxin in a Limulus amebocyte assay. 
Production of Rabbit Antiserum  against rLelE  An adult rabbit 
(New Zealand White; R & R Rabbitry, Stanwood, WA) was im- 
munized with 200/~g s.c. of purified rLelF in IFA (GIBCO BRL, 
Gaithersburg, MD) with 100/zg of muramyl dipeptide (adjuvant 
peptide; Calbiochem-Novabiochem Corp., La Jolla, CA), followed 
by a s.c. boost 4 wk later with 100 gg of the rag in IFA alone. 
After 3 wk, the rabbit was boosted with 25 gg i.v. of rLelF in 
saline, and serum collected 1 wk later. 
Cell Lysate.  Parasite and mammalian cell lysates were prepared 
by freeze-thaw lysis of pellets in SDS sample buffer without glycerol 
or B-ME. Insoluble material was separated  from the supernatant 
by centrifugation at 10,000 rpm. Protein concentrations were de- 
termined using a bicinchoninic acid protein assay kit (BCA; Pierce 
Chemical Co., Rockford, IL). 
Immunoblot  Analysis.  5-10/~g of parasite  or cell extracts or 
0.5-1.0 gg of rAg were separated on 12.5% SDS-PAGE and dec. 
trophoretically transferred to nitrocellulose membranes. Reactivi- 
ties of the antisera were assessed as previously described (12) using 
nSI-protein  A, followed by autoradiography. 
Patients.  Peripheral blood was obtained from individuals living 
in an area endemic for L. braziliensis (Corte de pedra, Bahia, Brazil) 
in which epidemiological,  clinical, and immunological studies of 
leishmaniasis have been performed for over a decade (3). Diagnosis 
was made by clinical findings associated with at least one of the 
following: parasite isolation, leishmanial  skin test, or positive se- 
rology. An epidemic in the field area without access to glucantime 
enabled us to detect patients who had healed spontaneously (self- 
healing). 
PBMC  Culture, Proliferation, and Cytokine  Assays.  Peripheral 
blood from Leishmania infected or uninfected individuals were col- 
lected and PBMC isolated from whole blood by density centrifu- 
gation through Ficoll (Pharmacia  Biotech Inc., Piscataway, NJ). 
For in vitro proliferation assays, 2-4  x  10  s cells/well were cultured 
in complete medium (RPMI 1640 supplemented with gentamycin, 
2-ME, t-glutamine, and 10% screened pooled A+  human serum; 
Trimar,  Hollywood, CA) in 96-well flat bottom plates  with or 
without 10 gg/ml of the indicated Ag or 5 gg/ml PHA (Sigma 
Immunochemicals, St. Louis,  MO) for 5 d. The cells were then 
pulsed with 1/zCi of [3H]thymidine for the final 18 h of culture. 
Data are represented as mean cpm of triplicate  cultures and the 
stimulation  index  (SI)  defined as  mean  cpm  of cultures  with 
Ag/mean  cpm  of cultures  without  Ag.  For determination  of 
cytokine production, PBMC were cultured at 1-2  x  106 cells/ml 
in medium containing endotoxin-free FCS (CeUect Gold; ICN Bio- 
medicals, Inc., Costa Mesa, CA) with or without leishmanial  Ag 
and in the presence or absence of human (Hu) rlL-10 (10 ng/ml, 
DNAX,  Palo  Alto,  CA),  anti-IFN-y  (10  /~g/ml;  Chemicon, 
Temucula, CA), or anti-IL-12 (Wistar Institute). Supernatants and 
cells were harvested and analyzed for secreted cytokine or cytokine 
mRNAs after 24 (for IL12) or 72 (for ILl0 and fiN-T) h of cul- 
ture as described  below. 
Cytokine ELISA.  Supernatants were assayed  for IFN-% TNF-oe, 
IL-4, and Ibl0. IFN-3' was quantitated by a double sandwich ELISA 
using mouse anti-Hu IFN-3' mAb (Chemicon) and polydonal rabbit 
anti-human IFN-3" serum. Hu rlFN-',/(Genentech Inc., San Fran- 
cisco, CA) was used to generate a standard curve. I1.-4 was quanti- 
tated in supernatants by a double sandwich ELISA using a mouse 
anti-human IL4 mAb (M1) and a polyclonal rabbit anti-human 
IL-4 sera (P3).  Hu rlL-4 (Immunex Corp., Seattle, WA) was used 
to generate a standard curve ranging from 50 pg/ml to 1 ng/ml. 
II.,10 was  measured using  a rat  anti-human  II.-10 mAb  (Cat.# 
18551D; PharMingen,) to capture secreted Ibl0 and a biotinylated 
rat anti-human IL-10 mAb (Cat.# 18562D;  PharMingen) for de- 
tection of bound IL-10 with streptavidin-conjugated horse radish 
peroxidase and ABTS as substrate.  A standard curve was obtained 
using Hu rlL-10 (kindly provided by DNAX Research  Institute, 
Palo Alto,  CA), ranging from 30 pg to 2 ng/ml.  Ib12 p40 was 
measured in cell-free supernatant by RIA (detection limit of 10 
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logically active IL-12 p70 heterodimer (detection limit 1 pg/ml) 
was measured as described (14). 
Cytoh'ne PCR.  For cytokine  analysis,  0.5-1 ml of  PBMC (1-2 x 
106 cells/m1) were cultured with or without Ag for 48 and 72 h. 
Supernatants and cells were harvested and analyzed for cytokine 
mRNAs or secreted  cytokines. For cytokine mRNA analysis,  total 
RNA was isolated from PBMC and cDNA synthesized using 
poly(dT) (Pharmacia, Piscataway,  NJ) and AMV reverse  transcrip- 
tase (Bethesda  Research  Laboratories,  Gaithersburg, MD) in a final 
volume of 20 #1. cDNA samples  were brought to 200/~1 with water. 
After normalization to B-actin, 12-20/~1 of diluted cDNA was 
amplified  by PCR using Taq polymerase  (Perkin-Elmer  Cetus, Nor- 
walk, CT) with 0.2 #M of the respective 5' and 3' external primers 
in a reaction volume of 50/~1. The conditions used were: denatura- 
tion at 94~  (1 min for fl-actin, Ib2, and Ib4; 45 s for IFN-3'; 
and 30 s for Ibl0), annealing at 55~  (1 min for fl-actin, Ib2, 
and IIz4; 30 s for IL-10)  or 60~  for 45 s for IFN-3' and elongation 
at 72~  We verified that our PCR conditions were within the 
semi-quantitative range by initially performing serial dilutions of 
cDNA and varying the number of cycles  used for PCR. In all sub- 
sequent experiments, 30 cycles  were used in the amplification  reac- 
tions for B-actin, II_-2, Ib4, and IFN-% In the case of Ibl0 PCR, 
25 cycles  were used. The primer pairs used were derived from pub- 
lished information: ~/-actin, Ib2, Ib4, and IFN-7 (15), and Ibl0 
(16). The nucleotide sequences for the 5' and 3' oligonucleotide 
primers, respectively,  are as follows:  B-actin, TGACGGGGTCACC- 
CACACTGTGCCCATCTA and CTAGAAGCATTGCGGTGG- 
ACGATGGAGGG;  IL,2, ATGTACAGGA'IGCAACTCCTGTCTT 
and GTCAGTGTTGAGATGATGCTTTGAC;  Ib4, ATGGGTCT- 
CACCTCCCAACTGCT and CGAACACTTTGAATATTTCTC- 
TCTCAT; IFN-% ATGAAATATACAAGTTATATCTTGGCTTT 
and GATGCTCTTCGACCTCGAAACAGCA~,  Ibl0, TCTCAA- 
GGGGCTGGGTCAGCTATCCCA  and ATGCCCCAAGCTGAG- 
AACCAAGACCCA. 
Inserts were isolated from plasmids containing the human se- 
quences for Ib2, IFN-3', IL-4, IL-10, and fl-actin and radiolabeled 
32p-probes generated as described (17). PCR products were ana- 
lyzed by dectrophoresis on 1.5% agarose gels, transferred to nylon 
membranes, and probed with the appropriate szp-labeled  DNA in- 
sert. Hybridizations were at 55~  overnight. Posthybridization 
washes were at 55~  for 20 min twice each with 2x  and lx  SSC 
containing 0.2%  SSC. 
Nucleotide Sequence Accession Number.  The nucleotide sequence 
of pLelF has been submitted to the EMBL/GenBank/DDBJ/Data 
Bank under accession number U19888. 
Results 
Molecular  Cloning  and  Sequence  Characterization  of  L. 
braziliensis  Ribosomal elF4A.  As part of a strategy for iden- 
tifying  leishmanial Ag, we screened a L. braziliensis  genomic 
expression library with sera from a ML patient, purified im- 
munoreactive rAg, and analyzed them in patient T cell assays 
for  their  ability  to  stimulate  proliferative  responses  and 
preferential  Thl  cytokine  production.  This  led  to  the 
identification of several cDNAs. One of these was identified 
by GenBank sequence comparison as the L. braziliensis homo- 
logue of the eukaryotic initiation factor 4A (LelF). 
The open reading frame of the full-length LelF encodes  a 
protein of 403 amino acids and a predicted molecular mass of 
45.3 kD (not shown). The lengths (403, 413, 407,  and 395 
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amino acids), molecular mass (45.3, 46.8, 46.4, and 44.7 kD), 
and isoelectric  points (5.9,  5.4,  5.5,  and 4.9)  of 1,elF, and 
the homologous proteins from tobacco, mouse, and yeast re- 
spectively (18-20) are similar. 1.elF contains sequence elements 
characteristic of several demonstrated or putative ATP-depen- 
dent RNA helicases represented by the eukaryotic initiation 
factor 4A (elF4A). The elF4A is one of the best character- 
ized members of the "DEAD box" family of KNA helicases. 
These proteins share a series of conserved motifs, with two 
of them representing specialized versions of the A and B motifs 
previously described in other ATP-binding proteins (21). The 
four amino acid sequence Asp-Glu-Ala-Asp (DEAD) is part 
of the specialized  version of the B  motif. 
Southern analysis of  L. braziliensis  genomic DNA digested 
with enzymes that cut both within (PstI and NotI) and out- 
side (BamHI, EcoRI, EcoRV,  HindlII, PvulI, and SstI) of 
LelF and probed with an *0.94-kb  fragment (nuc!eotides 
143 to 1083) of the coding region of 1.elF revealed at least 
two copies of LelF (Fig.  1). The same figure also illustrates 
the cross-species conservation between l.eiF of L. braziliensis 
and other Leishmania species. Northern analysis revealed that 
LelF is transcribed as '~2.5 kb mRNA species (not shown). 
Expression,  Purification,  and  Immunoblot  Analysis  of 1.elF 
Ag.  Fig. 2 shows the expression and purification of the m45 
kD  LelF gene product.  Immunoblots of lysates  from L. 
braziliensis  as well as other Leishmania species (promastigote 
and amastigote stages) were performed with the polyclonal 
rabbit anti-LelF serum which detected one dominant pro- 
tein species of-45 kD. The immune rabbit sera did not react 
Figure  1.  Genomic  organization  of Leishmania elF4A. L.  braziliensis 
DNA (lanes  Lb, 2.5 #g per lane)  was digested  with BamHI  (lane  B), EcoRI 
(lane  RI), EcoRV  (lane  RV), Hindlll (lane  H), PvulI  (lane  Pv), SstI (lane 
S), NotI (lane  N), and PstI (lane  P). DNA from  L. chagasi (lane  Lc), L. 
donovani (lane  Ld), L. infantum (lane  LI), L. tropica (lane  Lt), L. major  (lane 
Lm), L. amazonensis (lane  La), L. guyanensis (lane  Lg), an uncharacterized 
protozoan species (lane  L'), T. cruzi (lane Tc), and T. brucei (lane Tb) were 
digested  with PstI. The blot was probed with a "~0.94-kb restriction  frag- 
ment of  l-elF  comprising  only  coding  sequences.  Numberings  indicate  the 
sizes in kb pairs of HindlI/HinclI-digested  X DNA. Figure 2.  Expression,  purification, and immunoblot  analysis  of 1.elF 
Ag. (A) Coomassie  blue-stained  12% SDS-PAGE  of  tool wt markers  (lanes 
M), E. coli lysates  from uninduced  (lanes 1) and induced  (lane  2) cultures 
and the purified  rAg (lanes  3). (B) Reactivities  of  a rabbit anti-rLelF  serum 
on L. braziliensis  and L. chagasi  promastigote  lysates  (lanes I and 2, respec- 
tively),  or L. arnazonensis  promastigote  and amastigote  stages  (lanes  3 and 
4, respectively). 
with E.  coli lysate (not shown), demonstrating the lack of 
E.  coli proteins in the purified rLelF. 
rLelF Stimulates PBMC from Leishmaniasis Patients  to Pro- 
liferate and to Express a Predominant Thl Cytokine Profile  Pur- 
ified rLelF was tested for its effectiveness  in stimulating T 
cells from L. braziliensis-infected individuals.  Proliferation and 
cytokine responses of PBMC from patients with active or 
healed CL,  ML,  or individuals with self-healing CL were 
compared using rLelF and L. braziliensis lysates. PBMC from 
most (>70%) ML and CL patients proliferated to rLelF with 
stimulation indices ranging from 12 to 233 and 2 to 64, respec- 
tively (Table  1).  PBMC  from all  six individuals with  self- 
healing CL proliferated in response to rLelF with stimulation 
indices (16-198) comparable to those of ML patients. PBMC 
from two of the self-healing individuals (MS and DJ), prolifer- 
ated to LelF to a greater degree than to lysate.  Cells from 
normal individuals were only marginally stimulated by LelF. 
The results demonstrate that rLelF is a potent T cell Ag rec- 
ognized by a majority of L.  braziliensis-infected  individuals 
in different stages  or manifestations of infection. 
A  more detailed analysis  of cytokine patterns of PBMC 
from patients with confirmed cases of L.  braziliensis  infec- 
tion was performed using PCR.  Fig. 3 A  shows the PCR 
results of cytokine mKNA for three of the six ML patients' 
PBMC analyzed (JV, SZ, and TE). Cytokine mRNA anal- 
yses were performed with freshly isolated PBMC (lanes 0), 
or PBMC cultured in the absence (lanes  -) or presence of 
rLelF.  In three of six patients (TE, Fig.  3 A; NO and EO, 
not shown), PBMC not cultured in vitro had detectable levels 
of mKNA for IFN-y and IL-4, and two were positive for 
IL-2 (patients TE and EO). IL-10 mKNA was not detected 
in uncultured ("resting") PBMC  from any of the ML pa- 
tients.  However, after in vitro culture without  Ag,  IL-10 
mKNA was upregulated in most of the ML patient PBMC 
analyzed. In addition, the levels of other cytokine mRNAs 
detected in the resting PBMC of patients TE, NO, and EO, 
decreased to background levels. In three of six patients, leish- 
mania1 lysate stimulated the expression of mRNA for the 
Thl cytokines (IFN-q, and IL-2) as well as for the Th2 cytokine 
IL-4. Increased IL-10 mRNA was detected in one of the pa- 
tients' PBMC (SZ, Fig.  3 A) after culture with leishmanial 
lysate.  In contrast, rLelF Ag elicited increased mKNA for 
IFN-'y and IL-2 from all ML patient PBMC,  an exclusive 
Thl cytokine profile. In fact, the addition ofLelF downregu- 
lated the production of IL-10 mRNA in the cultured PBMC 
of most ML patients  (Fig.  3 A,  lanes elF). 
Similar PCR analyses were performed on PBMC derived 
from CL patients.  The resting PBMC from three (VS, JP, 
and CA) of the four patients analyzed revealed readily de- 
tectable mKNA for both Thl  (IFN-3' and IL-2) and Th2 
(IL-4 and IL-10) associated cytokines (Fig. 3 B). Little or no 
mRNA for IFN-% IL-2, IL-IO, or IL-4 was detected in the 
resting PBMC of the fourth (AS) CL patient. Therefore, in 
contrast to ML patients, most patients with CL had RNA 
for IL-10 as well as for IL-4, IL-2, and IFN-3'. For most pa- 
tients, whereas the mRNA for IL-2 and IFN-y were reduced 
to barely detectable levels after the in vitro culturing of PBMC 
in  the absence of Ag,  mKNA  for  IL-10  remained either 
unaffected or increased. 
All CL patients tested responded to rLelF or to leishmanial 
lysate by upregulating the expression of mKNA for IL-2 and 
IFN-% However, IL-4 mRNA was also enhanced in one of 
the CL patients (AS) after stimulation with LelF.  In three 
of four patients (JP, VS, and AS), the level of IL-4 mKNA 
also increased after stimulation with parasite  lysate.  In the 
three patients (VS, JP, and CA) with resting levels of IL-IO 
mKNA,  rLelF  downregulated  their  expression  of  IL-IO 
mKNA.  We also  studied PBMC from a diffuse cutaneous 
leishmaniasis (DCL) patient (L.  amazonensis infection). In- 
terestingly, as with PBMC from patients with L. braziliensis 
infection, LelF downregulated IL-10 mRNA while increasing 
IFN-3' and IL-2 mRNA in the DCL patient VA (Fig. 3 B). 
PBMC from patient VA also proliferated in the presence of 
l.eiF but not in response to parasite tysate (Table 1). In general, 
the PCK products for IL-2 and IFN-q, of  patient PBMC after 
stimulation with l.eiF or parasite lysate were readily detected 
on ethidium bromide-stained gels, suggesting relative abun- 
dance, whereas IL-4 and IL-IO were detected only by radio- 
active  probing  of the resolved PCK products. 
The cytokine mRNA profiles of PBMC from self-healing 
CL were similar to those of ML patients in that (a), except 
for one individual (HS) with detectable levels of IL-10 mRNA, 
resting PBMC from three of the four patients (GS, AH, DJ, 
and HS) analyzed had detectable levels of IL-2, IFN-% and 
IL-4 but little or no IL-IO mKNA; (b) IL-IO mKNA was 
upregulated after culture of PBMC without Ag whereas those 
of IL-2, IFN-y, and IL-4 decreased to background levels and; 
(c), leishmanial lysate stimulated the expression of a mixed 
Thl/Th2  cytokine profile whereas LelF  elicited increased 
mRNA expression of only the Thl-type cytokines and down- 
regulated the expression of IL-10  mRNA  in the cultured 
PBMC  of most self-healing CL individuals (not  shown). 
To complement the cytokine mRNA analysis, we assayed 
PBMC culture supernatants for IFN-% TNF-ol, IL-4, and 
IL-10.  Cells from all three patient  groups  as well as from 
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[3H]TdR incorporation  (mean cpm [SD]  x  10 -3) 
Patients  Media  Lysate  LelF 
ML  SI  SI 
JV  0.15  (0.0)  41.30  (1.3)  294  11.90 (4.8)  81 
SZ  0.45  (0.1)  140.60 (7.6)  308  105.90 (5.6)  233 
AB  0.42  (0.3)  44.20  (0.5)  104  5.00 (1.3)  12 
NO  0.38  (0.1)  52.70  (3.3)  138  12.80 (1.6)  33 
TE  0.18  (0.0)  27.40  (1.5)  150  8.80  (0.3)  48 
MB  0.18  (0.0)  300.10  (9.4)  1634  41.50  (4.5)  226 
OM  0.28  (0.0)  35.40  (3.2)  124  6.90 (2.5)  24 
CL 
AS  0.22  (0.0)  19.14 (1.3)  87  14.30 (2.3)  64 
JP  0.25  (0.0)  55.63  (8.6)  218  4.40  (0.3)  17 
VS  0.17  (0.0)  0.26  (0.0)  1.5  0.30  (0.0)  2 
RJ  0.10  (0.0)  0.32  (0.2)  3.0  1.50 (0.6)  15 
JA  0.16  (0.0)  0.77  (0.1)  4.7  2.50  (0.2)  16 
AD  4.20  (1.0)  4.01  (1.0)  2.0  14.10 (2.2)  3.5 
HN  0.36  (0.0)  4.73  (1.7)  13  4.69 (1.7)  13 
DCL 
VAL  0.22  (0.0)  0.51  (0.3)  2.0  2.12  (0.2)  9.0 
SH-CL 
GS  0.21  (0.0)  19.70 (4.4)  94  41.50  (2.8)  198 
MS  0.09  (0.0)  0.60  (0.1)  6.5  5.10 (2.1)  57 
AH  0.11  (0.0)  59.60 (7.1)  519  9.60 (4.7)  83 
DJ  0.12  (0.0)  0.20  (0.1)  1.6  19.00 (6.7)  151 
HS  0.12  (0.0)  27.10  (2.0)  225  12.40 (2.7)  103 
MCT  0.38  (0.0)  130.30 (14)  340  6.20  (1.5)  16 
Normal 
LV  0.14  (0.0)  0.19  (0.0)  1.4  0.71  (0.1)  4.0 
VV  0.18  (0.0)  0.31  (0.1)  1.7  0.28  (0.1)  1.5 
N3  0.14  (0.0)  0.36  (0.1)  2.6  0.27  (0.1)  1.9 
N4  0.59  (0.1)  2.00  (0.3)  3.8  0.56  (0.0)  1.0 
a DCL patient (VA) secreted IFN-3' and TNF-ot after stimu- 
lation  with  rLelF  (Fig.  4).  The levels  of both  IFN-3' and 
TNF-ot in the supernatants of patient PBMC (0.3-26 ng/ml 
and 0.1-3 ng/ml, respectively)  were significantly  higher com- 
pared to those from uninfected controls.  In the absence of 
rLelF stimulation,  only PBMC from ML patients  (five of 
six) produced detectable levels of supernatant  TNF-ot (60- 
190 pg/ml).  Little or no IL-4 or IL-10 were detected in any 
of the supernatants  analyzed (not shown), indicating levels 
below the detection limit of the ELISA assay employed. By 
comparison, leishmanial  lysate also stimulated patient PBMC 
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to secrete IFN-3' and TNF-c~ and,  in some patients,  IL-10 
was also detected (not shown). Therefore, and in agreement 
with the PCR cytokine analysis, whereas the cytokine profile 
of patient PBMC stimulated with LelF reflects an exclusive 
Thl  pattern,  parasite  lysate stimulates  a  mixed  Thl/Th2 
cytokine profile. 
l_elF Downregulates the LPS-induced IL-IO Production by Pa- 
tient PBMC.  Taken together, the above results demonstrate 
that rLelF elicits a predominant  Thl  cytokine profile from 
the PBMC ofML, CL, or DCL patient while downregulating 
the  expression  of IL-10  mRNA.  To  further  demonstrate Figure 3.  PCR amplification  of cytokine  mRNAs (IL-2, IFN-"/, IL.IO, and 11_,4) isolated from ML (A) and CL (/3) patients' PBMC before and 
after stimulation  with the indicated  Ag. The amount of cDNA synthesis  reactions used in the cytokine  PCR was normalized to the 3-actin PCR 
product (not shown). (Lanes  O and -) PCR products at the initiation  of culture or after 72 h of culture in the absence of Ag. PCR products after 
culturing  of PBMC  with L. braziliensis  lysate  (lanes  Lb), and rLelF  (lanes  elF) Ag. After  hybridization  with the respective  cytokine  probes, the autoradio- 
graphs were exposed either at room temperature (11.,2 and IFN-"/) for 30 min to 1 h or at  -70~  for 6 h to overnight (11.-10 and 1I-,4). 
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Figure  4.  Supernatant  levels  of IFN-3~ (.4) and TNF-~ (B) determined 
by ELISA  from 72 h cultures of PBMC from Leishmania infected  (ML, 
CL, and self-healing  CL [SH-CL]) and control (NORMAL) individuals 
in response to stimulation  with parasite lysate  (I) or rLelF  (2). Each  value 
represents an individual  patient. Mean values are indicated with a dash 
for each group. 
directly the effect of LelF in downregulating IL-10 produc- 
tion, PBMC from three ML patients were cultured in the 
presence of LPS with or without I.eiF. LPS stimulated PBMC 
from all three individuals tested to secrete IL-10 with values 
ranging from 185 to 424  pg/ml (Fig.  5).  However, in the 
presence of LelF, the production of LPS-induced IL-10 secre- 
tion was reduced by 49-65% (83-166 pg/ml). Because IFN-y 
can inhibit IL-10 production by activated macrophages (22) 
and I.eiF stimulated patient PBMC  to secrete IFN-"/, the 
secreted IFN-'y may be responsible  for partially inhibiting 
the production of LPS-induced IL-10, 
LelF Stimulates  both Patient  and Normal PBMC to Secrete 
IL-12.  IL-12 has been shown to play a pivotal immunoregu- 
latory role in the development of cell-mediated immunity, 
including the generation of  Thl responses and IFN-3' produc- 
tion in intracellular bacterial or parasitic infections (23). IL-12 
is a heterodimeric molecule comprised of p40 and p35 subunits 
which must be coexpressed  for the production of biologi- 
cally active IL-12 p70 (24). The p40 subunit is produced only 
by IL-12-producing cells and is induced in vitro and in vivo 
after bacterial and parasitic stimulation (13, 25), whereas the 
p35 subunit is both ubiquitous and constitutively expressed. 
Therefore, cells producing IL-12 p70 also have a large excess 
(lO-100-fold) of  biologically  inactive free 1040 chains (13). Be- 
cause LelF stimulated a dominant Thl cytokine profile and 
downregulated Th2 responses,  we explored a possible  role 
for IL-12 in PBMC responses to rLelF. Fig. 6 A  shows that 
l_eiF stimulated IL-12 p40 production from patient PBMC 
with values consistently higher than those observed with para- 
site lysate, and that IL-10 abrogated the production of IL-12 
p40 by patient PBMC after stimulation with either LelF or 
parasite  lysate. 
PBMC from uninfected individuals also produced IL-12 
p40 when cultured with LelF (Fig.  6 B), although no p40 
was detected in response to parasite lysate. This may suggest 
a role for IFN-~/in the lysate-induced p40 observed  in pa- 
tient PBMC, which produced 5-100-fold more IFN-'y than 
normal PBMC after antigen stimulation (Fig.  4 A). 
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Figure 5.  I.eiF  downregulates  the  LPS-induced  ID10 
production by PBMC. Cells from three ML patients (EU, 
JN, and RC) were cultured in the absence (Med) or presence 
of LeIF (10 #g/m1), LPS (1 #g/ml) or LPS and LeIF together 
and the supernatant levels of IL-10 determined after incuba- 
tion for 3 d. 
To determine whether the IL-12 p40 production observed 
in Ag-stimulated PBMC cultures  reflected biologically ac- 
tive cytokine, IL-12 p70 was also determined  in these cul- 
tures (Fig. 6, C and D). In general, the p70 production pat- 
tern paralleled that of p40, demonstrating that biologically 
active IL-12 was produced in response  to LelF in both pa- 
tient and normal PBMC. 
Production of lFN-9/ by LelF-stimulated Patient PBMC is IL- 
12 Dependent  and Is Downregulated by IL-IO.  The above results 
indicated  that the production of IFN-'y by patient PBMC 
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Figure 6.  I.elF stimulates PBMC to secrete IL-12 p40 and p70. Cells from (A and C) ML patients (JN, EU, andJV) and (B and D) three uninfected 
individuals (DI, D2, and D3) were cultured in the absence (Med) or presence of leishmanial lysate (Lb), LelF, or l.eiF and IL-10 and the supernatants 
from 24-h cultures assayed for secreted IIr  p40 and p70. 
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Figure  7.  Dependence  of II:12 production on IFN-y. Supernatants from 
ML PBMC were assayed for II:12 p40 in the absence of Ag stimulation 
(Med), in the presence of Ag (l_elF  and Lb) or Ag and anti-IFN-y mAb. 
after stimulation with LelF or parasite lysate may be medi- 
ated by IL-12. LelF stimulated higher IL-12 p40 in patient 
PBMC than in normal PBMC indicating that the produc- 
tion of IL-12 may be upregulated by IFN-% To determine 
the interaction between IL-12, IFN-y, and IL-10 in response 
to LelF, PBMC from ML patients were stimulated in vitro 
with LelF in the absence or presence of anti-IL-12, anti-IFN-y 
mAb, or IL-10, and the cultured supernatants were assayed 
for IFN-q, and II.-12 p40 secretion. The addition of anti-IFN-3, 
mAb reduced the I.eIF-induced production of IL-12 by 65 
and 80% but abrogated the lysate-induced  IL-12 (Fig.  7). 
Both anti-IL-12  mAb and IL-10 abrogated the production 
of LelF-induced IFN-7 (Fig. 8 A) whereas anti-IL-12 mAb 
only partially decreased the production of IFN-q, after stim- 
ulation with leishmanial lysate (Fig. 8 B). Exogenous IL-IO 
abrogated IL-12 p40 production by patient PBMC in response 
to either LelF or lysate (Fig. 8). IL-10 has also been shown 
to inhibit IL-12 production by human PBMC (26) and by 
human myeloid leukemia cell lines (14). These results indi- 
cate that the production of IFN-3, by LelF-stimulated pa- 
tient PBMC is IL-12 dependent, whereas the production of 
IL-12 is regulated by both IFN-q,-dependent and -indepen- 
dent pathways. 
Discussion 
We have cloned and characterized rLeIF, a Leishmania Ag, 
that elicits proliferation and a Thl-type cytokine profile from 
a leishmaniasis patient PBMC. Although resting and lysate 
stimulated PBMC from L. braziliensis-infected individuals have 
a mixture of Thl- and Th2-1ike cytokine profiles, rLelF shifted 
this pattern  towards an exclusive Thl  (IFN-3'  and IL-2) 
cytokine profile. In addition, rLelF stimulated both patient 
and normal PBMC to produce IL-12 whereas lysate did not 
stimulate the production of IL-12 in uninfected individuals. 
Finally, both rLelF and parasite lysate stimulated PBMC from 
ML and self-healing CL patients to secrete TNF-ot. The ob- 
servation that LelF stimulated T cells from all patients with 
self-healing CL to proliferate  and produce IFN-'y suggests 
that PBMC responses to LelF may be associated with protec- 
tive immunity. In  contrast,  we  have  identified other  L. 
braziliensis Ag that stimulate patient PBMC to produce a mixed 
Thl/Th2 or a predominant Th2 cytokine profile or that stimu- 
late PBMC from ML patients but not from self-healing indi- 
viduals (Skeiky, Y.A.W., et al., manuscript in preparation). 
Thus, l.eiF appears to have unique immunological properties. 
Cytokines appear to be essential mediators of immunity 
to Leishmania (27). IFN-3, and TNF-o~ may synergize to in- 
duce leishmanicidal activity in macrophages (28-30). In ad- 
dition, TNF-ol and IL-2 can also synergize with IL-12 to 
stimulate IFN-y production by NK cells (31-33).  Studies in 
mice have demonstrated that IL-12 (0.25-1/.tg/d) can induce 
IL-10 production (34, 35). Another study using human mono- 
cytes has demonstrated that the addition of TNF-ot (5-10 
rig) can  also induce IL-10 production (36).  In our study, 
TNF-c~ and IL-12 but not IL-IO were produced by patient 
PBMC stimulated with l.eiF. This may be due to the rela- 
tively lower level of either TNF-ot or IL-12 produced by pa- 
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Figure  8.  Interdependence of IFN-3' and IL-12  production and their abrogation by IL-10  after stimulation  of patient PBMC with LelF. (A) Production 
of IFN-y by PBMC from three ML patients (JN, EU, andJV) cultured in the absence (Med) or presence of LelF, I.eiF, and antiqb12 mAb (Anti-ILl2) 
or LelF and Ibl0. (B) Same as in A  but with parasite lysate. 
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high amounts by patient PBMC, to inhibit the production 
of IL-10 (22). The use of patient PBMC, rather than purified 
cell populations, may be more relevant to the in vivo situa- 
tion since the dominant cytokine pattern is dependent on 
the interplay of modulatory cytokines. 
The  presence of a  mixture  of Thl  and  Th2  cytokine 
mRNAs in the resting PBMC of ML patients is similar to 
the cytokine profile reported in lesions of ML patients (37, 
38), although in our study, IL-IO mRNA was not detected 
in the resting PBMC from any of the ML patients character- 
ized. However, IL-IO mRNA was detected after in vitro cul- 
ture of ML patient PBMC in the absence of Ag. In contrast, 
resting PBMC from CL patients had, in addition to mRNA 
for IL-4 and IFN-% detectable levels of IL-10 mRNA which 
remained generally unaffected after culture in the absence of 
Ag.  Therefore, the levels of cytokine mRNA in unstimu- 
lated controls may reflect an activated state from in vivo ex- 
posure to parasite  Ag. In this regard, rLelF downregulated 
the resting/constitutive levels of IL-IO in patient PBMC's as 
well as in LPS-stimulated PBMC.  It therefore appears  that 
certain Leishmania Ag may be able to elicit a dominant Thl 
cytokine profile as well as inhibit  the production  of Th2 
cytokines (IL-10) by mechanisms that are not fully understood. 
Because IL-12 plays a central role in the initiation and main- 
tenance of Thl responses in humans and mice (23,  39-43) 
and is a potent inducer of IFN-3, (33) which can inhibit the 
production of IL-10 (22), we reasoned that rLelF may be medi- 
ating a dominant Thl cytokine profile by an IL-12-depen- 
dent mechanism. Manetti et al.  (41) showed that patients 
with allergies who have mixed Thl/Th2 cytokine patterns 
could be shifted towards an experimentally induced Thl pheno- 
type by the addition of IL-12.  A  significant finding of the 
present study was the demonstration that rLelF stimulated 
patient PBMC to produce IL-12 and that the production of 
IFN-3/was, at least in part, IL-12 dependent. Other studies 
have demonstrated a role for II,-12 in enhancing IFN-'y produc- 
tion in both mouse and human cells (44, 45). Recent studies 
from several groups have led to the conclusion that the dom- 
inant factor of Thl cell development in response to infection 
may be determined by the ability of the pathogen to stimu- 
late IL-12 production by macrophages. In this regard, several 
pathogens  including L.  monocytogenes, Toxoplasma gondii, 
Mycobacterium tuberculosis, Staphylococcus aureus, and L. major, 
that induce a Thl response correlate with their capacity to 
stimulate the production of IL-12 (13,  14, 24,  32,  43,  44, 
46, 47). However, the components or factors responsible for 
stimulating IL-12 production remain to be identified. 
Our results have demonstrated that a single component 
of Leishmania is capable of stimulating the production of IL- 
12. This study represents the first reported identification of 
a recombinant parasite  protein that stimulates the produc- 
tion of IL-12 in both patient and normal PBMC. Therefore, 
our finding that LelF can stimulate IL-12 production as well 
as the elicitation of an exclusive Thl cytokine profile in pa- 
tient PBMC indicates that LelF could confer protective im- 
munity against Leishmania infections and/or act as an adju- 
vant. In human peripheral blood, monocyte/macrophages are 
the major source of IL-12 although B cells and other minor 
populations of HLA-DR + accessory cells also produce IL-12 
(13). Our preliminary results indicate the monocytes/macro- 
phages population of patient PBMC as the dominant IL-12- 
producing cell types after stimulation with LelF. In addition, 
I.eiF stimulated purified monocytes from uninfected individ- 
uals to produce IL-12 but not IL-10, thus suggesting the di- 
rect ability of 1.elF to function as an adjuvant (Skeiky Y. A. W., 
M. Kubin, G. Trinchieri, and S. G. Reed, manuscript in prep- 
aration). The mechanisms by which l.eiF induce IL-12 produc- 
tion are currently being investigated. 
In summary, we have identified a Leishmania Ag that stimu- 
lates IL-12 and elicits a dominant Thl-type cytokine profile 
in human PBMC. An ideal prophylactic and therapeutic vac- 
cine for leishmanial infection would be one that induces the 
expansion of Ag-specific Thl cells. These cells would pro- 
duce IFN-y and IL-12  which would promote parasite  de- 
struction within the macrophage and downregulate Th2 re- 
sponses. Because Leishmania I.eiF induced a powerful Thl-type 
response, including the two cytokines most clearly associated 
with protection in experimental leishmaniasis, IFN-'y and IL- 
12,  LelF is an antigen that merits further study. 
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